Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.

Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether hormone therapy is more effective when given with or without everolimus in treating breast cancer.

June 11, 2015
June 11, 2015
Breast Cancer
Amaryllis Gil, MD
Elmhurst Hospital

This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer. 

View more information on S1207 at

Accepting Participants
Kathy Seymour, BSN
(331) 221-2168